

Registered Office :

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GIDC - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451

Date: August 05, 2023

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai - 400051.

Dear Sir,

Sub: Intimation of Board meeting for consideration of Unaudited Financial Results for quarter ended on June 30, 2023.

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of our Company is scheduled to be held on Friday, August 11, 2023, at the registered office of the Company situated at Plot No. PF-21, Nr. Acme Pharma, Opp. Teva Pharma Sanand GIDC-II, Sanand Ahmedabad-382110, inter alia, to;

1. Consider, approve & take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2023 as per Regulation 33 of the Listing Regulation;
2. Consider and discuss any other items as may be decided by the Board of Directors of the Company.

In this connection, we would like to inform that, Our Company is SME listed company, listed on Emerge platform of NSE, the declaration of quarterly results for the quarter ended June 30, 2023 is not applicable to our company in lieu of exemption provided under Regulation 33 of SEBI LODR Regulations, 2015. However, Board of directors decided to voluntarily declare quarterly results for the quarter ended June 30, 2023.

In this regards, Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and Company's Code of Internal Procedures and Conduct for Prevention of Insider Trading in Securities, the trading window for dealing in Equity Shares of the Company by the Insiders covered under Company's Code of Internal Procedures and Conduct for Prevention of Insider Trading in Securities will be closed from Saturday, August 05, 2023 till 48 hours after the declaration of Financial Results for the quarter ended June 30, 2023.

Accordingly, all Designated Persons of the Company have been informed not to trade in the securities of the Company during the aforesaid period of closure of trading window. Also we assure you that, the Designated Persons of the Company have not traded in the securities of the Company after the closure of the reporting quarter. i.e. June 30, 2023.

Kindly take the same on your record and oblige us.

Thanking you,

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad